TYRA

Tyra Biosciences has delivered a 54.9% gain over the past 3 years, which means anyone looking at the stock today now has to ask whether that share price is still grounded in the company’s book value.

Tyra Biosciences has delivered a 31.8% gain over the past 3 years, yet the recent pullback in the share price raises a practical question for investors who watch fundamentals closely.

Tyra Biosciences (TYRA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Tyra Biosciences, Inc. (NASDAQ:TYRA) reported initial Phase 2 SURF302 results on September 9 for dabogratinib, an investigational oral FGFR3 inhibitor.

Tyra Biosciences has seen its share price swing sharply around recent trial updates and capital plans, which puts a fresh spotlight on what investors are really paying for against its book value.

Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment.

Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.

Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.

Tyra Biosciences (NASDAQ:TYRA) shares dropped 30% on Wednesday after the biotechnology company released initial results from its Phase 2 SURF302 trial of dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer.